AR050642A1 - Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina - Google Patents

Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina

Info

Publication number
AR050642A1
AR050642A1 ARP050103781A ARP050103781A AR050642A1 AR 050642 A1 AR050642 A1 AR 050642A1 AR P050103781 A ARP050103781 A AR P050103781A AR P050103781 A ARP050103781 A AR P050103781A AR 050642 A1 AR050642 A1 AR 050642A1
Authority
AR
Argentina
Prior art keywords
antibody
antigen
human
humanized
chimeric
Prior art date
Application number
ARP050103781A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35811702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050642(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR050642A1 publication Critical patent/AR050642A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anticuerpos anti-5T4 quiméricos y humanizados y conjugados anticuerpo/fámaco, y métodos para preparar y utilizar los mismos. Reivindicacion 1: Un anticuerpo anti-5T4 quimérico o humanizado que comprende al menos una cadena liviana o al menos una cadena pesada, o un fragmento quimérico o humanizado del mismo, donde el anticuerpo o fragmento de anticuerpo (a) se une específicamente al antígeno 5T4 humano con una afinidad de union de al menos aproximadamente 1 x 10-7 M a aproximadamente 1 x 10- 12 M; (b) se une específicamente al antígeno 5T4 humano con una afinidad de union mayor que 1 x 10-11 M; (c) se une específicamente al antígeno 5T4 humano con una afinidad de union mayor que 5 x 10-11M; (d) se une específicamente al antígeno 5T4 humano con una afinidad de union mayor que una afinidad de union del anticuerpo H8 murino anti-5T4 al antígeno 5T4 humano; (e) se dirige específicamente a célula que expresan 5T4 in vivo; (f) compite por la union al antígeno 5T4 humano con cualquier anticuerpo de (a)-(e); (g) se une específicamente a un epítope unido por cualquiera de (a)-(e); o (h) comprende un dominio de union al antígeno de cualquiera de (a)-(e). Reivindicacion 48: Un método para tratar a un sujeto que padece un cáncer 5T4- positivo, comprendiendo dicho método administrar al sujeto una cantidad terapéuticamemnte efectiva de un conjugado anticuerpo anti-5T4/fármaco que comprende (i) un anticuerpo o fragmento de anticuerpo anti-5T4 quimérico o humanizado y (ii) un agente terapéutico que se une directa o indirectamente al anticuerpo o fragmento de anticuerpo anti-5T4 quimérico o humanizado.
ARP050103781A 2004-09-10 2005-09-09 Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina AR050642A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60849404P 2004-09-10 2004-09-10

Publications (1)

Publication Number Publication Date
AR050642A1 true AR050642A1 (es) 2006-11-08

Family

ID=35811702

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103781A AR050642A1 (es) 2004-09-10 2005-09-09 Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina

Country Status (22)

Country Link
US (3) US20060088522A1 (es)
EP (1) EP1786469A2 (es)
JP (1) JP2008512485A (es)
KR (1) KR20070050956A (es)
CN (1) CN101035564A (es)
AR (1) AR050642A1 (es)
AU (1) AU2005285152A1 (es)
BR (1) BRPI0515113A (es)
CA (1) CA2578131A1 (es)
CR (1) CR8958A (es)
EC (1) ECSP077310A (es)
GT (1) GT200500255A (es)
IL (1) IL181625A0 (es)
MX (1) MX2007002826A (es)
NO (1) NO20071436L (es)
PA (1) PA8645301A1 (es)
PE (2) PE20060817A1 (es)
RU (1) RU2007108716A (es)
SV (1) SV2007002227A (es)
TW (1) TW200616662A (es)
WO (1) WO2006031653A2 (es)
ZA (1) ZA200702793B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
MXPA05001933A (es) * 2002-08-19 2005-04-28 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
PL1994055T3 (pl) * 2006-03-10 2015-02-27 Wyeth Llc Przeciwciała anty-5T4 i ich zastosowanie
CA2661848C (en) 2006-09-01 2015-02-03 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
KR20090069330A (ko) * 2006-10-12 2009-06-30 와이어쓰 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
US20080247955A1 (en) * 2007-01-16 2008-10-09 Jun Kuai Inflammation treatment, detection and monitoring via TREM-1
PE20090309A1 (es) * 2007-06-04 2009-04-18 Wyeth Corp Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
BRPI0819262A2 (pt) 2007-11-08 2017-05-02 Neogenix Oncology Inc anticorpos monoclonais recombinantes e antìgenos correspondentes para cânceres de cólon e pancreático
EP2796466B1 (en) 2007-12-07 2017-11-22 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31
FR2930443B1 (fr) * 2008-04-29 2010-06-25 Oreal Produit extemporane de soin a base d'un lyophilisat de microorganisme et de tensioactif(s) de hlb superieur ou egal a 12
CN102083859B (zh) * 2008-05-07 2014-09-17 阿哥斯医疗公司 人源化抗人干扰素-α抗体
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
EP3517961B1 (en) * 2009-01-09 2020-12-30 Oxford BioMedica (UK) Limited Factors
EP2411508B1 (en) 2009-03-27 2013-03-20 Wyeth LLC Tumor-initiating cells and methods for using same
CA2791652C (en) 2010-03-02 2018-06-12 Kyowa Hakko Kirin Co., Ltd. Modified antibody composition
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
US20140079722A1 (en) * 2011-03-09 2014-03-20 Centrose, Llc Extracellular targeted drug conjugates
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
WO2012131527A1 (en) * 2011-04-01 2012-10-04 Wyeth Llc Antibody-drug conjugates
SG194875A1 (en) 2011-05-08 2013-12-30 Legochem Biosciences Inc Protein-active agent conjugates and method for preparing the same
MX2014003313A (es) * 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Moleculas de union biespecificas para 5t4 y cd3.
WO2013068874A1 (en) * 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
MX361058B (es) * 2012-01-24 2018-11-23 Pfizer Método para detectar células tumorales circulantes 5t4-positivas y métodos de diagnóstico de cáncer 5t4-positivo en un sujeto mamífero.
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
PE20150223A1 (es) * 2012-06-15 2015-02-11 Pfizer Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
ES2786083T3 (es) 2012-12-12 2020-10-08 Arch Oncology Inc Anticuerpos terapéuticos CD47
US10316080B2 (en) 2013-10-11 2019-06-11 Asana Biosciences, Llc Protein-polymer-drug conjugates
EP3054991B1 (en) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP3065780A1 (en) 2013-11-04 2016-09-14 Pfizer Inc. Anti-efna4 antibody-drug conjugates
CN106456714A (zh) * 2014-03-28 2017-02-22 纽约大学 Fgf23融合蛋白
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
LT3151865T (lt) 2014-05-22 2021-10-25 Byondis B.V. Prijungiamų vaistų vietai specifinis konjugavimas su antikūnais ir to pasekoje gaunami avk
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
SG11201609917PA (en) * 2014-05-29 2016-12-29 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
EP3699188A1 (en) * 2014-09-04 2020-08-26 Cellectis 5t4 (tpbg) specific chimeric antigen receptors for cancer immunotherapy
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
RU2017139797A (ru) * 2015-04-17 2019-05-17 Арсанис Байосайенсиз Гмбх Антитела, направленные против иммуноглобулин-связывающих белков s. aureus
CA2929542A1 (en) * 2015-05-13 2016-11-13 Pfizer Inc. Treatment with anti-efna4 antibody-drug conjugates
BR112018005322A2 (pt) 2015-09-18 2018-12-11 Arch Oncology, Inc. anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
WO2017051254A1 (en) * 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-egfr antibody drug conjugates
WO2017051249A1 (en) * 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
CN112807429A (zh) 2015-11-19 2021-05-18 雷维托普有限公司 用于对非所要细胞进行重定向杀灭的两组分系统的功能性抗体片段互补作用
MY187325A (en) 2015-11-24 2021-09-22 Byondis Bv Anti-5t4 antibodies and antibody-drug conjugates
KR20180079452A (ko) 2015-11-25 2018-07-10 주식회사 레고켐 바이오사이언스 자기-희생기를 포함하는 접합체 및 이의 제조방법
EP3380126A4 (en) 2015-11-25 2019-07-24 LegoChem Biosciences, Inc. ANTIBODY-MEDICINAL CONJUGATES COMPRISING BRANCHED LINKS AND RELATED METHODS
CA3006247A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Conjugates comprising peptide groups and methods related thereto
WO2017106129A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
WO2017107973A1 (zh) * 2015-12-24 2017-06-29 凯惠科技发展(上海)有限公司 一种tpbg抗体及其制备方法、其偶联物和应用
US20170281758A1 (en) * 2016-03-29 2017-10-05 Sorrento Therapeutics, Inc. Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
EP3445788B1 (en) 2016-04-22 2022-01-19 Alligator Bioscience AB Novel bispecific polypeptides against cd137
GB201611530D0 (en) 2016-07-01 2016-08-17 Alligator Bioscience Ab Novel polypeptides
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
CN108084265B (zh) * 2016-11-23 2021-07-02 复旦大学 特异性结合人的5t4抗原的全人源单域抗体及其应用
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
CA3056542A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method
AU2018246806B2 (en) 2017-03-29 2022-05-12 Ligachem Biosciences Inc. Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof
EP3608335A4 (en) * 2017-04-05 2020-04-29 XDCExplorer (Shanghai) Co., Ltd. HUMANIZED ANTI-TPBG ANTIBODY, PRODUCTION METHOD THEREFOR, CONJUGATE THEREOF AND APPLICATIONS
US11725060B2 (en) 2017-07-20 2023-08-15 Aptevo Reserch and Development LLC Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN108187065B (zh) * 2017-12-29 2023-04-28 广东众生药业股份有限公司 抗5t4抗体与美登素衍生物dm4偶联复合物及制备方法和用途
AU2019233523A1 (en) 2018-03-12 2020-10-01 Genmab A/S Antibodies
CN108642070B (zh) * 2018-04-11 2022-03-15 沈阳金石生物制药有限公司 特异性诱导肿瘤细胞凋亡的重组人Fc抗体及其制备方法、用途
CA3099680A1 (en) 2018-05-09 2019-11-14 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
JP2022513400A (ja) 2018-10-29 2022-02-07 メルサナ セラピューティクス インコーポレイテッド ペプチド含有リンカーを有するシステイン操作抗体－薬物コンジュゲート
WO2020127376A2 (en) 2018-12-17 2020-06-25 Alligator Bioscience Ab Novel polypeptides
WO2020127374A2 (en) 2018-12-17 2020-06-25 Alligator Bioscience Ab Novel polypeptides
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
WO2021048423A1 (en) 2019-09-12 2021-03-18 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
WO2022106869A1 (en) 2019-11-22 2022-05-27 Medimmune Limited Fusion proteins comprising an e2 ubiquitin or ubiquitin-like conjugating domain and a targeting domain for specific protein degradation
BR112022019841A2 (pt) * 2020-04-09 2022-12-06 Cytomx Therapeutics Inc Composições contendo anticorpos ativáveis
CN117836326A (zh) 2021-08-26 2024-04-05 协和麒麟株式会社 与cd116和cd131结合的双特异性抗体
AU2022386680A1 (en) 2021-11-09 2024-06-20 Tubulis Gmbh Conjugates comprising a phosphorus (v) and a camptothecin moiety
AU2023220523A1 (en) * 2022-02-21 2024-09-12 Concept To Medicine Biotech Co., Ltd. Anti-5t4 antibodies and uses thereof
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof
WO2024183811A1 (en) * 2023-03-08 2024-09-12 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-5t4 antibodies and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4970198A (en) * 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US4670198A (en) * 1985-06-17 1987-06-02 General Electric Company Binder system for the manufacture of nuclear fuel pellets, and the method and product thereof
US5037651A (en) * 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5079233A (en) * 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5108912A (en) * 1987-01-30 1992-04-28 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5053394A (en) * 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5869053A (en) * 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
WO1998055607A2 (en) * 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Tumor targeted vector
US7148035B1 (en) * 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6342221B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
DK1507556T3 (en) * 2002-05-02 2016-09-12 Wyeth Holdings Llc Calicheamicin derivative-carrier conjugates
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina

Also Published As

Publication number Publication date
PE20060817A1 (es) 2006-10-10
NO20071436L (no) 2007-06-08
CN101035564A (zh) 2007-09-12
US20060088522A1 (en) 2006-04-27
AU2005285152A1 (en) 2006-03-23
WO2006031653A3 (en) 2006-05-04
BRPI0515113A (pt) 2008-07-01
MX2007002826A (es) 2007-04-27
RU2007108716A (ru) 2008-10-20
TW200616662A (en) 2006-06-01
KR20070050956A (ko) 2007-05-16
IL181625A0 (en) 2007-07-04
PA8645301A1 (es) 2006-07-03
SV2007002227A (es) 2007-03-20
JP2008512485A (ja) 2008-04-24
GT200500255A (es) 2006-04-10
US20100021483A1 (en) 2010-01-28
ZA200702793B (en) 2010-09-29
EP1786469A2 (en) 2007-05-23
CA2578131A1 (en) 2006-03-23
PE20100251A1 (es) 2010-04-10
ECSP077310A (es) 2007-04-26
CR8958A (es) 2007-10-04
US20100173382A1 (en) 2010-07-08
WO2006031653A2 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
AR050642A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina
de Goeij et al. High turnover of tissue factor enables efficient intracellular delivery of antibody–drug conjugates
Weiner et al. New approaches to antibody therapy
EA200602183A1 (ru) Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
AR059809A1 (es) Anticuerpos anti-5t4 y sus usos
CY1118053T1 (el) Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea
AR064360A1 (es) Anticuerpos humanos que se enlazan a cd70 y usos de los mismos
WO2019215510A8 (en) Compositions and methods related to anti-cd19 antibody drug conjugates
EA200600275A1 (ru) Цитотоксический конъюгат, специфичный по отношению к са6 антигену, и способы его применения
CO6210734A2 (es) Conjugados de anticuerpo anti-rg-1
HRP20161338T1 (hr) Limfocitni antigen
MX2021010003A (es) Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
AR064109A1 (es) Anticuerpos humanos que se enlazan al cd22 y sus usos
PE20110797A1 (es) Anticuerpos anti mn
EA201000910A1 (ru) Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения
AU2018315127A1 (en) Anthracycline-based antibody drug conjugates having high in vivo tolerability
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
SG153825A1 (en) Multivalent immunoglobulin-based bioactive assemblies
MX2022016180A (es) Conjugados anticuerpo-fármaco que comprenden anticuerpos anti-b7-h3.
JP2007516232A5 (es)
Gilabert-Oriol et al. Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells
AR046094A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
WO2019168947A8 (en) Bifunctional proteins combining checkpoint blockade for targeted therapy

Legal Events

Date Code Title Description
FA Abandonment or withdrawal